GSK plc (LON:GSK) Insider Jonathan Symonds Buys 7,150 Shares

GSK plc (LON:GSK) insider Jonathan Symonds purchased 7,150 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of GBX 1,394 ($18.08) per share, for a total transaction of £99,671 ($129,258.20).

GSK Trading Down 3.1 %

LON GSK opened at GBX 1,407 ($18.25) on Thursday. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. The firm has a market cap of £57.41 billion, a PE ratio of 1,245.13, a P/E/G ratio of 1.24 and a beta of 0.31. GSK plc has a one year low of GBX 1,371.40 ($17.78) and a one year high of GBX 1,823.50 ($23.65). The firm’s fifty day moving average is GBX 1,549.30 and its two-hundred day moving average is GBX 1,596.52.

GSK Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be paid a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, November 14th. This represents a yield of 1.03%. GSK’s dividend payout ratio is presently 5,309.73%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on GSK shares. Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. Berenberg Bank reiterated a “buy” rating and set a GBX 1,820 ($23.60) price target on shares of GSK in a research note on Tuesday, September 10th. Citigroup cut their price target on shares of GSK from GBX 2,120 ($27.49) to GBX 1,900 ($24.64) and set a “buy” rating on the stock in a research note on Friday, July 5th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research note on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,850 ($23.99) price target on shares of GSK in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,842.50 ($23.89).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.